Innovent Biologics (1801) Price & Analysis

Compare

14 Followers

1801 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$28.65 - HK$83.25

Previous CloseN/A

Volume9.75M

Average Volume (3M)22.30M

Market Cap

$133.94B

Enterprise ValueHK$51.27B

Total Cash (Recent Filing)$7.88B

Total Debt (Recent Filing)¥2.83B

Price to Earnings (P/E)―

Beta1.02

Next Earnings

Aug 27, 2025

EPS Estimate

0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding1,651,585,900

10 Day Avg. Volume32,425,531

30 Day Avg. Volume22,304,869

Financial Highlights & Ratios

PEG Ratio1.07

Price to Book (P/B)4.82

Price to Sales (P/S)0.00

P/FCF Ratio-48.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$63.42

Price Target Upside-20.68% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Innovent Biologics News

PremiumCompany Announcements

Innovent Biologics’ New Drug Application for Advanced Renal Cell Carcinoma Accepted in China

8d ago

PremiumCompany Announcements

Innovent Biologics Announces Annual General Meeting and Key Resolutions

11d ago

PremiumCompany Announcements

Innovent Biologics Reports Over 40% Revenue Growth in Q1 2025

1M ago

PremiumCompany Announcements

Innovent Biologics’ Limertinib Gains Approval for First-Line Lung Cancer Treatment

2M ago

PremiumCompany Announcements

Innovent Biologics Announces Board Changes

2M ago

PremiumCompany Announcements

Innovent Biologics Announces Board of Directors Composition

2M ago

PremiumCompany Announcements

Innovent Biologics Updates Nomination Committee Terms

2M ago

PremiumRatings

Innovent Biologics: Strong Financial Performance and Promising Growth in Oncology and Beyond

2M ago

See All HK:1801 News

See All News >

Bulls Say, Bears Say

Bulls Say

ProfitabilityInnovent achieved profitability ahead of schedule, realizing better-than-expected profitability due to strong product revenue growth and one-off license fee income.

Regulatory ApprovalInnovent announced it had received marketing approval from the National Medical Products Administration for its next-generation ROS1 tyrosine kinase inhibitor, DOVBLERON, for the treatment of patients with 2L ROS1+ non-small cell lung cancer.

Strategic PartnershipsInnovent Biologics has out-licensed the global rights of a novel DLL3 ADC to Roche through a blockbuster deal, receiving an upfront payment and potential milestone payments, along with tiered royalties on net sales.

Bears Say

Market CompetitionDLL3-targeted therapy has become increasingly dynamic with significant transactions, highlighting the strategic value of Innovent Biologics' partnerships and assets.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

9.19%

Mutual Funds

― Other Institutional Investors

83.04% Public Companies and

Individual Investors

Detailed Ownership Overview >

1801 FAQ

What was Innovent Biologics’s price range in the past 12 months?

Innovent Biologics lowest stock price was HK$28.65 and its highest was HK$83.25 in the past 12 months.

What is Innovent Biologics’s market cap?

Innovent Biologics’s market cap is $133.94B.

When is Innovent Biologics’s upcoming earnings report date?

Innovent Biologics’s upcoming earnings report date is Aug 27, 2025 which is in 75 days.

How were Innovent Biologics’s earnings last quarter?

Innovent Biologics released its earnings results on Mar 26, 2025. The company reported HK$0.192 earnings per share for the quarter, beating the consensus estimate of -HK$0.245 by HK$0.437.

Is Innovent Biologics overvalued?

According to Wall Street analysts Innovent Biologics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Innovent Biologics pay dividends?

Innovent Biologics does not currently pay dividends.

What is Innovent Biologics’s EPS estimate?

Innovent Biologics’s EPS estimate is 0.2.

How many shares outstanding does Innovent Biologics have?

Innovent Biologics has 1,651,585,900 shares outstanding.

What happened to Innovent Biologics’s price movement after its last earnings report?

Innovent Biologics reported an EPS of HK$0.192 in its last earnings report, beating expectations of -HK$0.245. Following the earnings report the stock price went down -0.255%.

Which hedge fund is a major shareholder of Innovent Biologics?

Currently, no hedge funds are holding shares in HK:1801

Innovent Biologics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-0.72%

Trailing 12-Months

Asset Growth

1.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Innovent Biologics

Innovent Biologics, Inc. (1801) is a leading biopharmaceutical company based in China, focused on the development, manufacture, and commercialization of innovative and high-quality biologic therapies. The company primarily operates in the biotechnology and pharmaceutical sectors, with a strong emphasis on oncology, metabolic, autoimmune, and other major disease areas. Innovent's core products include a portfolio of monoclonal antibodies and biologics addressing some of the most challenging health conditions.

1801 Stock 12 Month Forecast

Average Price Target

HK$63.42

▼(-20.68%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"HK$31","84":"HK$84","44.25":"HK$44.3","57.5":"HK$57.5","70.75":"HK$70.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":83.99999997290664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.4193051928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$63.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.99999998774348,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,44.25,57.5,70.75,84],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.1,64.7076923056082,66.3153846112164,67.92307691682461,69.53076922243281,71.13846152804102,72.74615383364922,74.35384613925743,75.96153844486562,77.56923075047382,79.17692305608203,80.78461536169023,82.39230766729844,{"y":83.99999997290664,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.1,63.12456193790769,63.149123875815384,63.173685813723075,63.198247751630774,63.222809689538465,63.24737162744616,63.27193356535385,63.29649550326154,63.32105744116923,63.34561937907693,63.37018131698462,63.39474325489231,{"y":63.4193051928,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.1,61.16923076828796,59.23846153657592,57.30769230486388,55.37692307315184,53.4461538414398,51.51538460972776,49.58461537801572,47.65384614630368,45.723076914591644,43.792307682879596,41.86153845116756,39.93076921945552,{"y":37.99999998774348,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.7,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >